Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Challenges in treating infant ALL patients with CAR-T

Colleen Annesley • 7 Dec 2019
ASH 2019
Acute Lymphoblastic Leukemia Leukemia CAR-T

Colleen Annesley, MD, Seattle Children’s Research Institute, Seattle, WA, discusses the challenges of treating infant acute lymphoblastic leukemia (ALL) patients with CAR T-cell products, in particular because KMT2A-rearranged leukemia undergoing lineage switch following CD19-targeting pressure raises concern for an increased risk of myeloid leukemia relapse after B-lineage targeted CAR T-cell therapy in this population. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Colleen Annesley

1:46
Novel CD19t T-APCs enhance CD19 CAR T-cell persistance
Colleen Annesley • 7 Dec 2019
2:24
PLAT-02 and -05 trials for CAR-T in R/R infant ALL
Colleen Annesley • 7 Dec 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals